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ABSTRACT
Background and Objectives: Kawasaki disease (KD) is a multi-systemic vasculitis with coronary artery involvement. Se-
rum interleukin (IL)-6 levels during acute phase showed a significant correlation with the duration of fever in patients with 
KD who were not treated with intravenous immunoglobulin (IVIG), suggesting that the regulation of IL-6 expression in 
KD patients may differ from that in normal children. However, there are controversies surrounding the association between 
IL-6 (-636 C/G) gene polymorphism and development of KD. Subjects and Methods: One hundred and nine children 
with KD and 191 children with congenital heart disease were included in this study. Echocardiography was performed to 
examine cardiac involvement in patients with KD. Genotyping of the IL-6 (-636 C/G) gene polymorphism was performed 
using the single-base extension method, and serum IL-6 concentrations were estimated using the sandwich enzyme immu-
noassay method. Results: Neutrophil, platelet count, liver function test, total protein and albumin concentrations were sig-
nificantly different in the KD group and the serum IL-6 concentration was significantly higher in the KD group than the con-
trol group. There was no difference between the patients with coronary arterial dilatation (CAD) and those without CAD in 
the IL-6 (-636 C/G) polymorphism. The serum albumin concentration was significantly lower in patients with KD who had 
the -636 C/G or GG genotype compared with the control group. The serum IL-6 concentration was significantly higher in pa-
tients with KD who had the -636 C/G or GG genotype. Conclusion: There was no association between the IL-6 (-636 C/G) 
gene polymorphism and development of coronary arterial lesions in KD. Further multicenter studies are required to establish 
the relationship between the IL-6 (-636 C/G) gene polymorphism and development of KD. (Korean Circ J 2011;41:321-326)
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Introduction
Kawasaki disease (KD) is an acute, self-limited vasculitis 
that affects mainly infants and young children.
1)2) Ten to fif-
teen percent of patients with untreated KD develop coronary 
arterial lesions.
3-5) Although it has been shown that coronary 
complications can be significantly reduced by the use of high-
dose intravenous immunoglobulin (IVIG) therapy combin-
ed with oral acetylsalicylic acid, the etiology of KD still re-
mains unknown.
6) 
KD is known to involve an immune-mediated inflammato-
ry process that leads to endothelial cell damage.
7) The immu-
nological changes in KD are evidenced by an increase in serum 
levels of cytokines, such as tumor necrosis factor (TNF)-α, in-
terleukin (IL)-1, IL-2, IL-6, and interferon (IFN)-γ during the 
acute phase.
8)9) The stimulus for increased serum levels of 
cytokines remains unknown.
Polymorphisms in genes encoding these crucial immuno-
modulatory molecules may result in an altered level of expres-
sion, and hence must be considered important candidate genes 
for KD susceptibility and disease severity. The genetic suscep-
tibility to specific diseases may be identified by considering se-
veral genetic variants together.322   Interleukin-6 Polymorphism in Kawasaki Disease
IL-6 is a pro-inflammatory cytokine secreted by T cells and 
macrophages to stimulate an immune response leading to in-
flammation.
10) It is associated with atherosclerosis and myo-
cardial infarction
11) and is one of the most important media-
tors of fever and of the acute phase response. Serum IL-6 dur-
ing the acute phase showed a significant correlation with the 
duration of fever in patients who were not treated with IVIG. 
This suggests that the regulation of IL-6 expression in KD pa-
tients may differ from that in normal children, possibly due to 
gene polymorphisms.
12) However, there are controversies ab-
out the association between the IL-6 gene polymorphism 
and development of KD. Therefore, we studied the possible ge-
netic influence on the expression of IL-6 in KD patients by ex-
amining serum levels of IL-6 and the IL-6 (-636 C/G) gene po-
lymorphism. 
Subjects and Methods
The study group included 189 KD patients (108 males and 
81 females) with a mean age of 40.5 months from the Depart-
ment of Pediatrics at Ewha Womans University Hospital and 
the Asan Medical Center, Seoul, Korea. The subjects were all 
Koreans born in Seoul. 
All of the KD patients were treated with IVIG (2 g/kg/day 
for 1 day), and oral aspirin (50 mg/kg/day). Echocardiography 
was performed by pediatric cardiologists to detect the presence 
of coronary artery lesions prior to IVIG administration. Coro-
nary arteries were defined as abnormal if the internal lumen 
diameter was >3 mm in children younger than 5 years old and 
>4 mm in children 5 years old or more; if the internal diame-
ter of a segment measured ≥1.5 times that of an adjacent seg-
ment; or if the coronary lumen was clearly irregular.
13) The con-
trol group consisted of 191 children (88 males and 103 fema-
les) aged 29.0 months on average, with congenital heart disease 
which included ventricular septal defect (n=64), Tetralogy 
of Fallot (n=61), patent ductus arteriosus (n=33), atrial sep-
tal defect (n=20), total anomalous pulmonary venous return 
(n=7), and interrupted aortic arch (n=6).
14) None of the pa-
tients had congestive heart failure. 
Laboratory data were obtained from each child, including 
complete blood count (CBC), erythrocyte sedimentation rate 
(ESR), platelet count, alanine aminotransferase (ALT), aspar-
tate aminotransferase (AST), serum total protein, albumin, 
and C-reactive protein (CRP). Genomic DNA samples were 
extracted from their peripheral bloods before IVIG therapy 
in the KD patient group and before operation for their con-
genital cardiac abnormalities in the control group. 
The study was carried out with the approval of the ethics 
committee of Ewha Womans University Hospital and the 
Asan Medical Center Institutional Review Board, and writ-
ten informed consents were obtained from the parents of all 
subjects. 
Genotyping of the interleukin-6 (-636 C/G) gene 
polymorphism 
The genomic DNA was prepared from peripheral blood. 
The IL-6 (-636 C/G) single nucleotide polymorphism (rs180 
0796) was genotyped by using the single base extension me-
thod. PCR was performed in reaction mixtures containing 
1.25 pmol of each primer (sense, 5’-AGGATGGCCAGGC 
AGTTC-3’ and antisense 5’-CCAGTCATCTGAGTTCTT 
CTGTGTT-3’), 50 ng of genomic DNA, 250 mM dNTPs, 
and 0.15 U Taq DNA polymerase (Applied Biosystems, Fos-
ter City, CA, USA) in the buffer provided by the manufac-
turer. Amplification was performed in a GeneAmp PCR Sys-
tem 9700 thermal cycler (Applied Biosystems).
To clean up the PCR products for the primer extension 
reaction, each reaction mixture was incubated with 1 U of sh-
rimp alkaline phosphatase (SAP; Amersham Life Sciences, 
Cleveland, OH, USA) and 2 U of Exol (Amersham Life Sci-
ences) for 1 hour at 37°C, and then at 72°C for 15 minutes for 
enzyme inactivation. Primer extension reactions were per-
formed with a SNaP Shot ddNTP Primer Extension Kit (Ap-
plied Biosystems), according to the manufacturer’s instruc-
tions. The primer extension reaction products were cleaned 
up by incubation at 37°C for 1 hour in the presence of 1 U of 
SAP, followed by incubation at 72°C for 15 minutes. The ex-
tension products were then mixed with the Genescan 120 Liz 
size standard solution (Applied Biosystems) and Hi-Di forma-
mide (Applied Biosystems), incubated for 5 minutes at 95°C, 
placed on ice for 5 minutes, and then electrophoresed on an 
ABI Prism 3100 Genetic Analyzer (Applied Biosystems). The 
results were analyzed by using the ABI Prism GeneScan and 
Genotyper software packages (Applied Biosystems). 
 
Measurement of serum IL-6 
Serum samples were obtained from KD patients and con-
trol subjects. Venous blood was withdrawn in the acute febrile 
stage before IVIG treatment in KD patients. Serum IL-6 lev-
els were measured by using a sandwich enzyme immunoas-
say-based Quantikine Human Interleukine-6 kit (R&D sys-
tems Inc., Minneapolis, MN, USA), according to the manu-
facturer’s instructions. 
Statistical analysis 
Statistical Package for the Social Sciences (SPSS) 12.0K for 
Windows (SPSS Inc., Chicago, IL, USA) was used for all sta-
tistical analyses. Clinical characteristics, including CBC, 
ESR, platelet counts, ALT, AST, serum total protein, albumin, 
CRP, and total duration of fever were analyzed as a quantita-
tive trait. Differences in clinical phenotypes between groups 
were analyzed using the Mann-Whitney U-test. 
Unconditional logistic regression analysis adjusted for age 
and sex was used to calculate adjusted odds ratios (aOR), 95% 
confidence intervals (CI). A p<0.05 was considered statistically Hye Mi Ahn, et al.   323
significant.
Results
Clinical characteristics of study subjects 
Clinical characteristics are shown in Table 1. White blood 
cell (WBC) count (neutrophil), platelet count, ALT, AST, and 
total protein were significantly higher, and hemoglobin and 
albumin levels were significantly lower in the KD group com-
pared with the control group (p<0.05). Coronary arterial le-
sions in the KD group were noted in 104 patients (55.03%). 
Allele frequencies of the interleukin-6 (-636 C/G)
polymorphism in the Kawasaki disease group and
the control group 
The 189 study subjects and 191 patients in the control group 
were genotyped for the IL-6 (-636 C/G) polymorphism, and 
allele frequencies were examined. The genomic frequencies 
of the IL-6 (-636 C/G) polymorphism in the KD group were 
57.1% (108/189) for CC, 37.6% (71/189) for CG, and 5.3% 
(10/189) for GG. In the control group, these frequencies were 
52.9% (101/191) for CC, 42.9% (82/191) for CG, and 4.2% 
(8/191) for GG. The genotype frequencies of these samples 
were in accordance with Hardy-Weiberg equilibrium. The ge-
nomic and allelic frequencies of this polymorphism did not 
significantly differ between the KD group and the control 
group (Table 2). 
Association between the interleukin-6 (-636 C/G) 
polymorphism and clinical parameters in the 
Kawasaki disease group and the control group 
Clinical parameters were compared between the KD group 
and the control group according to allele frequencies. WBC 
count (neutrophil), platelet count, AST, ALT, and total protein 
were significantly higher in the KD group compared with the 
control group. Interestingly, albumin concentrations were sig-
nificantly lower in patients with KD with -636 C/G and those 
with GG genotypes, compared to those with the CC genotype 
(Table 3). 
 
Allele frequencies of the interleukin-6 (-636 C/G) 
polymorphism in Kawasaki disease children 
with and without coronary arterial lesions 
We determined whether the IL-6 polymorphism was asso-
ciated with coronary arterial lesions in children with KD. In 
the KD group without coronary arterial lesions, allele frequ-
encies were 54.2% (45/83) for CC, 39.8% (33/83) for CG, and 
6.0% (5/83) for GG. In the KD group with coronary arterial 
lesions, allele frequencies were 59% (59/100) for CC, 37% 
(37/100) for CG, and 4% (4/100) for GG. There was no dif-
ference in the IL-6 (-636 C/G) polymorphism according to 
coronary arterial lesions (Table 4). 
Serum interleukin-6 levels in the Kawasaki disease 
group and the control group 
Serum IL-6 concentrations were 2.72±6.49 ng/mL in the 
control group and 51.0±13.85 ng/mL in the KD group. Serum 
IL-6 concentrations were markedly elevated in the KD group 
compared with the control group (Fig. 1). 
Serum interleukin-6 levels in the Kawasaki
disease group with CC and CG+GG genotypes 
The serum IL-6 concentration was examined according to 
genotype. Serum IL-6 levels were 21.0±23.4 ng/mL in patients 
with KD who had the CC genotype and 69.3±30.9 ng/mL in 
Table 2. Allele frequencies of the IL-6 -636C/G polymorphism in 
children with Kawasaki disease and congenital heart disease
Genotype
Control group 
(n=191)
KD group
(n=189)
No. (%) No. (%) aOR (95%CI) 
IL-6 -636C/G
CC 101 (52.9) 108 (57.1) 1.00
CG 082 (42.9) 071 (37.6) 0.81 (0.53-1.23)
GG 08 (4.2) 10 (5.3) 1.17 (0.44-3.08)
CG+GG 090 (47.1) 081 (42.9) 0.84 (0.56-1.26)
CC+CG 183 (95.8) 179 (94.7) 1.00
Frequency (C) 000 (74.3) 000 (75.9)
p>0.05. IL: interleukin, KD: Kawasaki disease, aOR: adjusted odds 
ratio 
Table 1.  Clinical characteristics of study subjects
Clinical parameters*
Control group KD group
(n=191) (n=189)
Sex (M/F) 88/103 108/81†
Mean age (months) 29.0±41.5 40.5±31.1†
WBC (×10
3/mm
3 ) 10.3±3.80 013.2±5.9†00
Neutrophil (%) 38.3±16.4 63.4±19.0†
Hemoglobin (g/dL) 13.0±2.00 11.7±1.1†0
Platelet (×10
3/mm
3 ) 323.2±100.5 364.1±143.1†
CRP (mg/dL) NA 9.7±7.10
ESR (mm/hr) NA 52.9±33.10
AST (IU/L) 42.6±24.1 59.2±80.4†
ALT (IU/L) 21.9±17.1 64.6±79.3†
Protein (g/dL) 6.3±0.8 7.5±5.5†
Albumin (g/dL) 3.9±0.6 3.2±0.5†
Total duration of fever (days) NA 6.3±3.50
Coronary artery lesion (n) NA 104 (55.03%)
The significance of clinical parameters according to groups was an-
alyzed using the Mann-Whitney test. *Data are expressed as mean± 
standard deviation, †p<0.05 significantly different from control 
group. NA: not available, KD: Kawasaki disease, WBC: whole blood 
cell, CRP: C-reactive protein, ESR: erythrocyte sedimentation rate, 
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patients with the -636 C/G and those with the GG genotype 
(Fig. 2). 
Discussion
The etiology for KD remains unknown, but several studies 
have suggested the involvement of an immune-mediated pro-
cess. Cytokines such as IL-1, IL-6, IFN-γ, TNF-α are released 
inducing a series of inflammatory reactions leading to endo-
thelial cell injury and inflammation of small and medium-siz-
ed arteries, especially coronary arteries.
15-17) Cytokines with po-
lymorphic gene sequences are potential markers of disease 
susceptibility.
15)16) 
In recent years, it has been well demonstrated that inflam-
Table 3. Association between IL-6 -636 C/G alleles and clinical parameters in children with Kawasaki disease and children with congenital 
heart disease
Clinical parameters*
Control group KD group
CC (n=101) CG+GG (n=90)  CC (n=108) CG+GG (n=81)
Age (months) 27.6±36.3 028.9±45.0 42.6±31.5 38.3±30.8
WBC (×10
3/mm
3) 10.0±3.50 10.7±4.0 13.2±5.80 13.5±6.20
Neutrophil (%) 37.3±16.3 039.3±16.8 64.7±17.9 62.6±20.4
Hemoglobin (g/dL) 13.0±1.90 12.9±2.2 11.7±1.10 11.6±1.10
Platelet (×10
3/mm
3) 323.8±102.0 325.6±99.4 350.8±128.9 375.7±147.5
CRP (mg/dL) NA NA 10.5±7.70 8.9±6.2
ESR (mm/hr) NA NA 54.7±32.3 53.5±33.6
AST (IU/L) 38.8±16.0 046.9±30.0 59.0±85.4 061.6±76.4†
ALT (IU/L) 19.2±10.7 025.0±21.8 63.2±80.4 067.4±80.2†
Protein (g/dL) 6.4±0.8 06.2±0.8 8.1±7.6 6.8±0.8
Albumin (g/dL) 4.0±0.6 03.8±0.6 3.3±0.5 03.1±0.5†
Total duration of fever (days) NA NA 6.3±3.1 6.4±4.0
*Data are expressed as mean±standard deviation, †p<0.05 compared between CC genotype and CG+GG genotype in children with control 
group. NA: not available, KD: Kawasaki disease, WBC: whole blood cell, CRP: C-reactive protein, ESR: erythrocyte sedimentation rate, AST: 
aspartate aminotransferase, ALT: alanine aminotransferase
Table 4. Allele frequencies of the IL-6 -636 C/G polymorphism in Kawasaki disease children with and without early coronary arterial lesion
Genotype IL-6 -636 C/G
KD without coronary artery lesion (n=89) KD with coronary artery lesion (n=100)
aOR (95% CI)
No. (%) No. (%) 
CC 48 (53.93) 59 (59.00) 1.00
CG 35 (39.32) 37 (37.00) 0.86 (0.47-1.58)
GG 6 (6.74) 4 (4.00) 0.61 (0.15-2.40)
CG+GG 41 (46.06) 41 (41.00) 0.82 (0.46-1.48)
CC+CG 83 (93.26) 96 (96.00) 1.00
Frequency (C) 0.74 0.78
p>0.05. IL-6: Interleukin-6, KD: Kawasaki disease, aOR: adjusted odds ratio
Fig. 1. Serum IL-6 levels in Kawasaki disease group and control gr-
oup. Serum IL-6 level was markedly elevated in KD group com-
pared with control group. *p<0.05 significantly different from control 
group. IL-6: interleukin-6, KD: Kawasaki disease.
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Fig. 2. Serum IL-6 levels in KD group with CC and CG+GG geno-
type. Regarding the IL-6 gene polymorphism, compared with the 
CC genotype, the serum IL-6 level was significantly higher in the 
CG+GG genotype in the KD group. *p<0.05 significantly different 
from CC group. IL-6: interleukin-6, KD: Kawasaki disease. 
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matory molecules, as well as single nucleotide polymorphisms 
of genes encoding inflammatory mediators, may contribute to 
the development and progression of a large number of pa-
thologic conditions including cardiovascular disease.
18-21)
One commonly used technique to identify genetic risk fac-
tors for multifactorial diseases such as KD is the candidate 
gene approach, which directly examines the effects of genetic 
variants of a possibly contributing gene by an association 
study. To date, quite a number of genes have been examined, 
which are usually selected based on information regarding 
their function in inflammation, the immune response, and ot-
her biological mechanisms.
18) 
Single nucleotide polymorphisms (SNP) of pro-inflamma-
tory and anti-inflammatory genes may strongly influence the 
plasma levels and biological activity of the corresponding pro-
teins, with potentially important clinical implications.
22)23)
 Burns et al.
24) reported that the genetic variation in the IL-4 
gene or regions linked to IL-4, plays an important role in 
KD pathogenesis and disease susceptibility. Jin et al.
25) re-
ported that the IL-10 (-627 A/C) gene polymorphism may 
be associated with coronary aneurysms and low albumin in 
Korean children with KD. IL-6 expression was noted in sev-
eral diseases such as systemic lupus erythematosus,
26) spora-
dic Alzheimer’s disease,
27) and systemic onset juvenile ch-
ronic arthritis.
28) 
The IL-6 gene -174G>C and -572G>C gene polymorphi-
sms are associated with cerebral aneurysm.
28) Whether this 
association is due to the development, progression, or rup-
ture of such an aneurysm or represents survivor bias is un-
clear. Sohn et al.
29) examined the IL-6 gene polymorphism at 
+162 bp, +168 bp and -594 bp, and reported that the poly-
morphism was not associated with KD. In KD, IL-6 has been 
reported to rise more than any other cytokine and correlates 
with coronary complications.
15) 
There have been no reported studies about the association 
between the IL-6 (-636 C/G) polymorphism and KD. In this 
study, we investigated the association between the IL-6 (-636 
C/G) polymorphism (rs1800796) and KD. The IL-6 (-636 
C/G) polymorphism showed no difference in gene frequency 
between the KD group and the control group. There was no 
difference in the IL-6 (-636 C/G) polymorphism according 
to coronary arterial lesions either. Nonetheless, the serum 
IL-6 levels were significantly higher in the KD group than the 
control group and among the KD group, serum IL-6 levels 
were significantly higher in the CG+GG group compared to the 
CC group. Likewise, albumin concentrations were signific-
antly lower in the KD group than the control group and 
among the KD group, the CG+GG group showed lower levels 
than the CC group. Therefore, our findings suggest that the 
IL-6 (-636 C/G) polymorphism may be associated with risk 
factors of KD, such as a low albumin concentration. In addi-
tion, elevated serum IL-6 concentrations in the CG+GG ge-
notype suggests the possibility of a relationship between the 
IL-6 (-636 C/G) polymorphism and KD that needs to be an-
alyzed further.
Our studies have some limitations. The studied population 
is relatively small in number. We enrolled patients with conge-
nital heart disease as a control group instead of normal chil-
dren. Also there is a possibility of linkage disequilibrium with 
an unknown risk single nucleotide polymorphism and the 
lack of function-related experiments. There have been no 
reported studies on the relationship of the transcription acti-
vity of IL-6 in KD. SNPs on the IL-6 promoter could affect the 
transcription activity and furthermore the expression of IL-
6. Such SNPs could be a good candidate marker to study the 
transcriptional activity of IL-6.
In conclusion, we found that the IL-6 (-636 C/G) polymor-
phism was not associated with the development of KD or 
coronary arterial lesions. This study suggests however, that the 
IL-6 (-636 C/G) polymorphism might prove useful as a ge-
netic marker for the indicators of KD such as duration of fe-
ver, platelet count, and albumin concentration. Given the li-
mitations of our study, it is not possible to definitely rule out 
the direct correlation between the IL-6 (-636 C/G) polymor-
phism and KD. Further large scale studies will be needed to 
establish the relationship between IL-6 gene polymorphisms 
and KD. 
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